CUTIA THERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.35 HKD | +3.38% |
|
+2.23% | -33.06% |
| Apr. 30 | Cutia Therapeutics' Unit Receives Jiangsu Drug Manufacturing Certificate | MT |
| Apr. 30 | Cutia Therapeutics Submits NDA for Androgenetic Alopecia Treatment Spray; Shares Jump 6% | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Cutia Therapeutics is a China-based company mainly engaged in the research and development and manufacture of dermatological biological drugs. The Company is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The Company is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The Company conducts its businesses in the domestic market and overseas markets.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.804
CNY
Average target price
16.85
CNY
Spread / Average Target
+147.68%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.06% | 278M | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B |
- Stock Market
- Equities
- 2487 Stock
- News Cutia Therapeutics
- Cutia's Phase 3 Clinical Trial for Analgesic Cream Reaches Primary Endpoint; Shares Surge 12%
